2025-08-29 01:30:19
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Cipla Ltd posts jump in consolidated PAT to Rs. 714.72 crores during Q1FY22
Posted On : 2021-08-05 20:27:11( TIMEZONE : IST )
Cipla Ltd., has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.5569.28 crores during the period ended June 30, 2021 as compared to Rs.4666.58 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.714.72 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.413.38 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.8.85 for the period ended June 30, 2021 as compared to Rs.5.12 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 5569.28 crs | ₹ 4666.58 crs |  19.34% |
| Net Profit | ₹ 714.72 crs | ₹ 413.38 crs | 72.9% |
| EPS | ₹ 8.85 | ₹ 5.12 | 72.85% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.5569.28 crores during the period ended June 30, 2021 as compared to Rs.4411.61 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.714.72 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.577.91 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.8.85 for the period ended June 30, 2021 as compared to Rs.7.16 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 5569.28 crs | ₹ 4411.61 crs | 26.24% |
| Net Profit | ₹ 714.72 crs | ₹ 577.91 crs | 23.67% |
| EPS | ₹ 8.85 | ₹ 7.16 | 23.6% |
"At Cipla, we feel proud to have contributed extensively to the fight against covid-19 amid the second wave by ensuring continuous supply of life-saving medicines. I am pleased to see the robust demand led traction in core therapies across our branded markets and continued cost control leading to 27% revenue growth and 24.5% EBITDA margin for the quarter. In India, we maintained our market beating performance as core therapies responded to demand triggers along with support from covid portfolio during the second wave. I am delighted to witness the continued unlocking of our respiratory franchise in the US with market share expansion in Albuterol and strengthening of the portfolio with Arformoterol launch. Our South Africa private business continues to outperform the market. Our investments in creating a differentiated API portfolio have helped drive growth in the quarter" - Umang Vohra MD and Global CEO, Cipla Ltd.
Shares of Cipla Ltd., was last trading in BSE at Rs. 945.2 as compared to the previous close of Rs. 939.6. The total number of shares traded during the day was 227413 in over 5850 trades.
The stock hit an intraday high of Rs. 952.85 and intraday low of 932. The net turnover during the day was Rs. 214753421.
